News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Videos|August 31, 2023

Chapter 4. Optimal Treatment Outcomes for Treating Patients With ADHD

Sponsored by: Ironshore Pharmaceuticals

Episodes in this series

EP. 1 Chapter 1. History of Stimulants in ADHD

EP. 1 Chapter 1. History of Stimulants in ADHD

EP. 2 Chapter 2. Guidance and Recommendations for the use of Stimulants in Adults With ADHD

EP. 2 Chapter 2. Guidance and Recommendations for the use of Stimulants in Adults With ADHD

EP. 3 Chapter 3. Pharmacokinetic Profiles of Long-Acting Stimulants

EP. 3 Chapter 3. Pharmacokinetic Profiles of Long-Acting Stimulants

EP. 4 Chapter 4. Optimal Treatment Outcomes for Treating Patients With ADHD

EP. 4 Chapter 4. Optimal Treatment Outcomes for Treating Patients With ADHD

EP. 5 Chapter 5. Adult Perspectives on ADHD Medications

EP. 5 Chapter 5. Adult Perspectives on ADHD Medications

EP. 6 Chapter 6. Optimizing the Duration of Effect with Stimulant Medications

EP. 6 Chapter 6. Optimizing the Duration of Effect with Stimulant Medications

EP. 7 Chapter 7. Stimulant Prescribing Practices for Patients With ADHD

EP. 7 Chapter 7. Stimulant Prescribing Practices for Patients With ADHD

EP. 8 Chapter 8. Managing Patient Expectations During Treatment for ADHD

EP. 8 Chapter 8. Managing Patient Expectations During Treatment for ADHD

EP. 9 Appropriate Use of Stimulant Medications in Adults With ADHD

EP. 9 Appropriate Use of Stimulant Medications in Adults With ADHD

IP001858 08/23

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

depression

Navigating the Complexity of Major Depressive Disorder

ByRoger S. McIntyre, MD, FRCPC

March 18th 2024

Chapter 8. Managing Patient Expectations During Treatment for ADHD

By

August 31st 2023

Chapter 7. Stimulant Prescribing Practices for Patients With ADHD

By

August 31st 2023

Chapter 6. Optimizing the Duration of Effect with Stimulant Medications

By

August 31st 2023

Chapter 5. Adult Perspectives on ADHD Medications

By

August 31st 2023

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

Bridging the Categorical-Dimensional Divide: Exploring the PRiSM Diagnostic Instrument

Sex Differences and Lifestyle Changes in ADHD

Our Tower of Babel and the Future of Psychiatric Clinicians

© 2025 MJH Life Sciences^®

All rights reserved.